 | Up a level |
Journal Article
Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., Ott, H. W., Hofer, S., Pluetschow, A., Diehl, V., Engert, A. and Borchmann, P. (2010). No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann. Oncol., 21 (10). S. 2052 - 2061. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Boell, B., Pluetschow, A., Eichenauer, D., von Tresckow, B., Atta, J., Pfreundschuh, M., Michaela, F. B., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2015). GERMAN HODGKIN STUDY GROUP PHASE I TRIAL OF DOXORUBICIN, VINBLASTINE, DACARBAZINE, AND LENALIDOMIDE (AVD-REV) FOR ELDERLY HODGKIN LYMPHOMA PATIENTS-FINAL ANALYSIS. Haematologica, 100. S. 322 - 323. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Boell, B., Pluetschow, A., Eichenauer, D. A., Thielen, I, von Tresckow, B., Atta, J., Pfreundschuh, M., Feuring-Buske, M., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2014). German Hodgkin Study Group Phase I trial of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) for elderly Hodgkin Lymphoma patients. Oncol. Res. Treat., 37. S. 12 - 13. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Eichenauer, D., Pluetschow, A., Kreissl, S., Fuchs, M., Soekler, M., Engel, N., Mathas, S., Behringer, K., Kobe, C., Dietlein, M., Diehl, V. and Engert, A. (2014). TARGETED BEACOPP VARIANTS IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS OF A RANDOMIZED PHASE II STUDY. Haematologica, 99. S. 497 - 499. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P. J., Goergen, H., Pluetschow, A., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS. Haematologica, 101. S. 4 - 5. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eich, H. T., Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Pluetschow, A., Fuchs, M., Engert, A. and Baues, C. (2016). FINAL RESULTS OF A QUALITY ASSURANCE PROGRAM WITHIN THE GERMAN HODGKIN STUDY GROUP HD13/14 TRIAL - A REPORT FROM THE RADIOTHERAPY REFERENCE PANEL INTEGRATING MODERN GUIDELINES. Haematologica, 101. S. 14 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eichenauer, D. A., Goergen, H., Pluetschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Broeckelmann, P. J., Fuchs, M., Boell, B., von Tresckow, B., Borchmann, P. and Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30 (6). S. 1425 - 1429. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Borchmann, P. and Engert, A. (2017). Long-term outcome of patients with early-stage nodular lymphocyte-predominant hodgkin lymphoma (NLPHL) treated within the randomized HD7, HD10 and HD13 trials: An analysis from the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 40. S. 142 - 143. BASEL: KARGER. ISSN 2296-5262
Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Diehl, V., Borchmann, P. and Engert, A. (2017). LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 82 - 83. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. -G, Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). Final analysis of a randomized phase II trial with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma -PVAG-14 pilot-. Oncol. Res. Treat., 37. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. G., Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Gillessen, S., Pluetschow, A., Fuchs, M., Markova, J., Greil, R., Topp, M., Meissner, J., Zijlstra, J., Eichenauer, D., Broeckelmann, P., Diehl, V., Borchmann, P., Engert, A. and von Tresckow, B. (2020). Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 88 - 90. BASEL: KARGER. ISSN 2296-5262
Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfart, K., Lukas, P., Pluetschow, A., Schmidberger, H., Staar, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). Quality control of involved field radiotherapy in the HD 13 and HD 14 trials. Strahlenther. Onkol., 193 (2). S. 109 - 116. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Analysis of the Quality Assurance Program of the Involved Field Radiotherapy within the HD13 and HD14 Study the German Hodgkin Study Group. Strahlenther. Onkol., 191. S. S10 - 2. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K. K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E449 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL. Haematologica, 101. S. 12 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL. Haematologica, 101. S. 13 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078